CA2573745A1 - Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2 - Google Patents

Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2 Download PDF

Info

Publication number
CA2573745A1
CA2573745A1 CA002573745A CA2573745A CA2573745A1 CA 2573745 A1 CA2573745 A1 CA 2573745A1 CA 002573745 A CA002573745 A CA 002573745A CA 2573745 A CA2573745 A CA 2573745A CA 2573745 A1 CA2573745 A1 CA 2573745A1
Authority
CA
Canada
Prior art keywords
composition
immunoglobulins
glycan
antibody
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573745A
Other languages
English (en)
Inventor
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycofi Inc
Original Assignee
Glycofi, Inc.
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi, Inc., Tillman U. Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi, Inc.
Publication of CA2573745A1 publication Critical patent/CA2573745A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
CA002573745A 2004-07-21 2005-07-19 Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2 Abandoned CA2573745A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59001104P 2004-07-21 2004-07-21
US59005104P 2004-07-21 2004-07-21
US60/590,011 2004-07-21
US60/590,051 2004-07-21
PCT/US2005/025652 WO2006014679A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2

Publications (1)

Publication Number Publication Date
CA2573745A1 true CA2573745A1 (fr) 2007-01-12

Family

ID=35262113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573745A Abandoned CA2573745A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2

Country Status (5)

Country Link
EP (1) EP1776385A1 (fr)
JP (1) JP2008512353A (fr)
AU (1) AU2005269759A1 (fr)
CA (1) CA2573745A1 (fr)
WO (1) WO2006014679A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2006094034A1 (fr) * 2005-03-01 2006-09-08 Wyeth Composes de cinnoline et leur utilisation comme modulateurs du recepteur hepatique x
CA2637254A1 (fr) * 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions et methodes destinees a l'humanisation et a l'optimisation de n-glycanes chez des plantes
TWI414531B (zh) 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
CN101855244A (zh) * 2007-08-01 2010-10-06 葛兰素集团有限公司 新型抗体
CN102216452B (zh) 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
SG177764A1 (en) * 2009-07-30 2012-03-29 Hoffmann La Roche Enzymatic antibody processing
UA104663C2 (en) 2010-01-28 2014-02-25 Глаксо Груп Лимитед Antibody binding to cd127
CN102834413A (zh) 2010-02-09 2012-12-19 葛兰素集团有限公司 代谢障碍的治疗
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
PL2643352T3 (pl) 2010-11-23 2018-10-31 Glaxo Group Limited Białka wiążące antygen wiążące onkostatynę M (OSM)
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
EP4338754A2 (fr) 2011-05-27 2024-03-20 Glaxo Group Limited Protéines de liaison à l'antigène
BR112014001855A2 (pt) 2011-07-27 2017-02-21 Glaxo Group Ltd construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
WO2014029752A1 (fr) 2012-08-22 2014-02-27 Glaxo Group Limited Anticorps anti-lrp6
ME03796B (fr) 2013-03-15 2021-04-20 Glaxosmithkline Ip Dev Ltd Protéines de liaison anti-lag-3
AP2017009765A0 (en) 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
JP7074341B2 (ja) 2015-09-02 2022-05-24 イムテップ エス．アー．エス． 抗ｌａｇ－３抗体
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
RU2018138122A (ru) 2016-04-05 2020-05-12 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новая терапия
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018102746A1 (fr) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Molécules de liaison à l'antigène destinées à la tigit
WO2019075090A1 (fr) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
WO2021207449A1 (fr) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Anticorps anti-lap à maturation d'affinité et leurs utilisations
EP4255928A1 (fr) 2020-12-02 2023-10-11 GlaxoSmithKline Intellectual Property Development Limited Protéines de liaison à il-7 et leur utilisation en thérapie médicale
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
WO2023017483A1 (fr) 2021-08-13 2023-02-16 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant ccr2
WO2023017484A1 (fr) 2021-08-13 2023-02-16 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité
CA3233953A1 (fr) 2021-10-05 2023-04-13 Matthew Bruce Polytherapies pour le traitement du cancer
WO2023161881A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant ccr2
WO2023161875A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant l'antigène membranaire spécifique de la prostate
WO2023161876A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant cxcr3
WO2023161878A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour cellules exprimant le récepteur du folate
WO2023161877A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant l'intégrine avb6
WO2023161879A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant des protéines d'activation de fibroblastes
WO2023161874A1 (fr) 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Chimères ciblant la cytotoxicité pour des cellules exprimant le récepteur 2 de la chimiokine c-c
WO2023212304A1 (fr) 2022-04-29 2023-11-02 23Andme, Inc. Protéines de liaison à un antigène
WO2023227641A1 (fr) 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Utilisation de protéines de liaison au tnf-alpha et de protéines de liaison à l'il-7 dans un traitement médical
WO2024042112A1 (fr) 2022-08-25 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison à l'antigène et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028751B1 (fr) * 1997-10-31 2008-12-31 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes

Also Published As

Publication number Publication date
WO2006014679A1 (fr) 2006-02-09
EP1776385A1 (fr) 2007-04-25
AU2005269759A1 (en) 2006-02-09
JP2008512353A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
US20060029604A1 (en) Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060024292A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
CA2573745A1 (fr) Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
US20060034829A1 (en) Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060034830A1 (en) Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060257399A1 (en) Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
AU2005269763A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
WO2006071856A2 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
CA2573541A1 (fr) Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb>
US20090226464A1 (en) Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
CA2620515A1 (fr) Immunoglobulines comprenant principalement une glycoforme glcnacman3glcnac2
CA2590441A1 (fr) Immunoglobulines comprenant principalement un glycoforme galglcnacman5glcnac2
CA2573554A1 (fr) Immunoglobulines comprenant principalement une glycoforme man<sb>5</sb>glcnac<sb>2</sb>
CA2573864A1 (fr) Immunoglobulines comprenant principalement une glycoforme glcnacman<sb>5</sb>glcnac<sb>2</sb>
CN101001875A (zh) 主要包含man5glcnac2糖形的免疫球蛋白
CN101001876A (zh) 包含占优势的GlcNacMAN5GLCNAC2糖形的免疫球蛋白

Legal Events

Date Code Title Description
FZDE Dead